Unternehmens-Profil
Merck & Co., Inc. operates as a leading healthcare company worldwide, focusing on human health pharmaceuticals, vaccines, and animal health products. Its portfolio includes blockbuster drugs like Keytruda for immuno-oncology, Gardasil for human papillomavirus prevention, and a range of treatments such as Welireg, ProQuad, Winrevair, Januvia, and others addressing cancer, infectious diseases, cardiometabolic conditions, and more. The company also provides veterinary solutions including Nuflor and Bovilis for livestock health management. With a substantial presence in oncology, its Keytruda leads sales contributions, complemented by vaccines targeting pediatric diseases. Merck & Co., Inc. generates significant revenue—$64.17 billion in 2024—from pharmaceuticals and vaccines, primarily in the U.S., while maintaining a diversified global footprint across consumer, business, and government sectors. Employing around 75,000 people, it plays a pivotal role in advancing treatments for chronic and infectious diseases, driving innovation in biopharmaceuticals and immunotherapy.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 112,3 USD· Stand 07.05.2026
News · Merck & Co., Inc.
- 2 Dividend Stocks to Double Up On Right Now
- Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
- 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash
- Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
- Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds